Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Plaza Centers N.V. (PLZ.WA)
Amsterdam, NL
Currently, Plaza Centers N.V. conducts no substantial business activities. In the past, the company was actively engaged in the creation, operation, and divestment of shopping and entertainment complexes, alongside various mixed-use developments encompassing retail, office, and residential spaces. These extensive projects were primarily situated across Central and Eastern Europe and India. Established in 1993, the entity adopted its present name, Plaza Centers N.V., in October 2006, having previously been known as Plaza Centers (Europe) B.V. The company's corporate base is located in Amsterdam, the Netherlands.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.95% | -7.26% | -9.00% | -54.21% | -40.57% | -40.08% | -41.76% | -30.33% | +21.33% | -92.72% | -99.86% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Real Estate - Development: +9.7%+670.7% ★ Q4'25: +6,944.2% (vs Q4'23)
-
EPS growth Real Estate - Development: +20.5%+35.9% ★ Q4'25: +22.0% (vs Q4'23)
-
FCF margin FCF growth · Real Estate - Development: +16.2%-4,101.6% Q4'25: -1,321.7% (vs Q4'23)
-
EBIT margin Real Estate - Development: +19.8%-599.6% Q4'25: -13,961.9% (vs Q4'23)
-
ROIC Real Estate - Development: +3.2%— Q4'25: +25.4% (vs Q4'23)
-
Share dilution Real Estate - Development: +0.0%+0.3% Q4'25: -2.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Real Estate - Development: 1.93×-38.04× Q4'25: -5.33× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ron Hadassi | Executive Officer & Executive Director | 182.0K | male |
| David Dekel | Independent Non-Executive Chairman & Compliance Officer | 70.0K | male |
| Advocate Uzi Eli Attorney | General Counsel | — | — |
| Mor Dagan | Investor Relations Professional | — | female |
| Ran Jacobs | Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PLZ.WA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
